/
KTTA
$0.53-$0.02 (-3.18%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$18.2M
33M shares
52-week range
$0.28 – $2.06
14% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
9.89%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-70.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $15.1K | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $17.3K | $5.1K | $0 | $0 | $0 |
| Gross profit | $0 | −$2.2K | −$5.1K | $0 | $0 | $0 |
| Gross margin | — | -14.7% | — | — | — | — |
| R&D | $0 | $0 | $2.7M | $8.1M | $7.2M | $8.0M |
| Operating income | −$61.5K | −$4.5M | −$12.6M | −$16.0M | −$14.2M | −$20.9M |
| EBITDA | $0 | −$4.5M | −$11.7M | −$15.3M | −$13.6M | −$20.2M |
| Net income | −$61.5K | −$2.2M | −$13.9M | −$16.0M | −$13.9M | −$20.4M |
| Net margin | — | -14430.5% | — | — | — | — |
| EPS (diluted) | -0.06 | -1.89 | -10.34 | -13.01 | -12.69 | -2.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.76 | $-0.76–$-0.76 | 1 |
| 2027 | $0 | $-1.01 | $-1.01–$-1.01 | 1 |
| 2028 | $0 | $-1.30 | $-1.30–$-1.30 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.85
Price
$0.53
Implied upside
+1391%
Peer comparison
Pasithea Therapeutics Corp. Common Stock
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
www.pasithea.com- Employees
- 5
- IPO / List date
- Sep 15, 2021
- HQ
- MIAMI BEACH, FL
Held by traders on TradeandTell
No one on the platform currently holds KTTA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 93,399 | $69.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-01-02 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded KTTA yet.
